Reports
Sale
Geographic Atrophy Market Size, Share, Growth, Analysis: By Age Group: 60-75 Years, Above 75 Years; By Treatment: Medications, Supplements, Others; By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy; Regional Analysis; Market Dynamics: SWOT Analysis, PESTEL Analysis; Supplier Landscape; 2024-2032
Geographic Atrophy Market Size
The geographic atrophy market was valued at USD 24.1 billion in 2023, driven by the increasing prevalence of geographic atrophy and the rising regulatory approval of new therapeutic agents across the 8 major markets. The market is expected to grow at a CAGR of 5.70% during the forecast period of 2024-2032, with the values likely to reach USD 39.9 billion by 2032.
Geographic Atrophy Market Outlook
- The increasing number of patients affected by geographic atrophy and the growing aging population are poised to fuel the market demand.
- One of the major market trends is the rising strategic collaborations and acquisitions between the key market players in order to accelerate the development of new treatments and expand their product portfolios.
- Increased focus on the clinical development of biologics and gene therapy solutions to treat geographic atrophy is projected to propel market growth.
Geographic Atrophy Market Overview
Geographic atrophy (GA) is the atrophic late form of age-related macular degeneration (AMD) and causes the destruction of retinal cells responsible for vision. It is reported to affect over 1 million individuals in the United States and around 5 million individuals globally. This progressive condition is predominantly found in older adults. Thus, as the aging population increases, the demand for the geographic atrophy market is expected to witness a surge.
The market is influenced by the growing awareness regarding this severe eye disease and its impact on vision. This is prompting more patients to seek early diagnosis and treatment. The growth in new drug approvals by regulatory bodies such as the FDA and EMA is also anticipated to aid in the market expansion. Moreover, factors such as significant investment in research and development in the retinal ophthalmology field, increased strategic partnerships among biotech and pharmaceutical companies, and advancements in diagnostic tools are expected to drive market growth.
Geographic Atrophy Market Growth Drivers
Increasing Prevalence of Geographic Atrophy Drives Market Growth
Recent data suggests that 1 out of 5 individuals aged 85 or more are affected by geographic atrophy in at least one eye. Bilateral geographic atrophy is reported to result in severe visual impairment, with a substantial burden on patients as well as healthcare providers. Although the prevalence and incidence of this eye disease varies across different regions, it is estimated that the highest burden of geographic atrophy is found in European ancestry. The increasing aging population is one of the primary drivers of the growing cases of this retinal disorder, which is anticipated to bolster market growth in the coming years.
Rise in Drug Approvals to Meet Rising Geographic Atrophy Market Demand
In February 2023, global biopharma company Apellis Pharmaceuticals, Inc. announced that the United States Food and Drug Administration (FDA) granted approval to its drug SYFOVRE™ (pegcetacoplan injection) indicated for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The regulatory approval, based on the positive results from the Phase 3 OAKS and DERBY clinical studies, marked a milestone in the field of retinal ophthalmology, with SYFOVRE being the first FDA-cleared treatment for geographic atrophy. The rise in such regulatory approvals is set to fuel the market growth.
Geographic Atrophy Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
| Key Trends | Impact |
| Growth in Strategic Partnerships | Many pharmaceutical companies are engaging in collaborations and acquisitions to accelerate the development of new treatments for retinal diseases including geographic atrophy. For instance, in December 2023, Japan-based Astellas Pharma Inc. completed the acquisition of United States biopharmaceutical company IVERIC Bio, Inc. to expand its portfolio in the ophthalmology disease segment. |
| Improvements in Diagnostic Technologies | The market is positively influenced by the improvements in diagnostic technologies, such as optical coherence tomography (OCT) and fundus autofluorescence (FAF). The adoption of such advanced diagnostic tools is resulting in early detection and better monitoring of the disease, which is expected to boost the geographic atrophy market value. |
| Increased Investment in Research and Development | One of the major market trends is the growing R&D funding by pharmaceutical companies which is aimed at discovering and developing new treatments for geographic atrophy. Such substantial investments are helping in better understanding the disease and bringing effective therapies to the market. |
| Advancements in Drug Development | The market is benefitting from the development of new therapeutic agents that are reaching late-stage clinical trials. These drugs are designed to target the underlying mechanism of this severe retinal disease and show the potential for better management of the condition. The rising focus on biologics and gene therapy solutions to treat geographic atrophy is projected to aid market expansion. |
Geographic Atrophy Market Segmentation
Market Breakup by Age Group
- 60-75 Years
- Above 75 Years
Market Breakup by Treatment
- Medications
- Supplements
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Geographic Atrophy Market Share
Distribution Channel Segment is Projected to Fuel Market Growth
Based on the distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. Hospital pharmacies cover a significant market share as they offer immediate access to medications for geographic atrophy in hospital settings. The online pharmacy segment is a growing market segment that allows patients to place orders for their medications remotely. Online pharmacies provide convenience and home delivery services and thus are gaining demand in the market.
Geographic Atrophy Market Analysis by Region
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States represents a significant market share owing to the large population in the region affected by age-related macular degeneration (AMD), including geographic atrophy. The market growth is supported by increased access to advanced therapies and the presence of a positive regulatory environment that ensures faster market entry for new treatments.
Leading Players in the Geographic Atrophy Market
The key features of the market report comprise the patent analysis, clinical trial analysis, grant analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Apellis Pharmaceuticals, Inc.
Based in Massachusetts, United States, Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company that is one of the leading players in the market. The company developed the first-ever treatment for geographic atrophy, SYFOVRE™ (pegcetacoplan injection), which the FDA approved in February 2023.
Iveric Bio
Iveric Bio, a part of Japan's Astellas Pharma, has a robust presence in the market and specializes in developing novel therapeutics for ophthalmic diseases. In August 2023, its therapy IZERVAY™ (avacincaptad pegol intravitreal solution) received FDA clearance for the treatment of geographic atrophy.
Alkeus Pharmaceuticals Inc.
United States-based Alkeus Pharmaceuticals Inc., a late-stage biopharmaceutical company, is known for developing therapies against serious and untreatable eye diseases. Its lead candidate Gildeuretinol acetate (ALK-001) is undergoing clinical development for geographic atrophy and Stargardt's disease.
Hemera Biosciences
Privately owned biotechnology company Hemera Biosciences is known for developing gene therapy to treat patients with age-related macular degeneration (AMD). The firm has developed drug candidate HMR59, a gene therapy designed to increase the expression of CD59, which has the potential to preserve vision in geographic atrophy patients.
Other key players in the market include Allegro Ophthalmics, Stealth BioTherapeutics, Novartis AG, Regenerative Patch Technologies, LLC, F. Hoffmann-La Roche AG, Gensight Biologics, NGM Biopharmaceuticals, AstraZeneca PLC, and Lineage Cell Therapeutics.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Age Group |
|
| Breakup by Treatment |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Questions Answered in the Geographic Atrophy Market Report
- What was the geographic atrophy market value in 2023?
- What is the geographic atrophy market forecast outlook for 2024-2032?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on age group?
- What is the market breakup based on treatment?
- What is the market breakup by distribution channel?
- What are the major factors aiding the geographic atrophy market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How does the prevalence and incidence of geographic atrophy affect the market landscape?
- What are the major geographic atrophy market trends?
- How does the rise in the geriatric population impact the market size?
- Which age group will dominate the market share?
- Which treatment is expected to have a high market value in the coming years?
- Which distribution channel is projected to contribute to the highest market growth?
- Who are the key players involved in the geographic atrophy market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Geographic Atrophy Market Overview: 8 Major Market
3.1 Geographic Atrophy Market Historical Value (2017-2023)
3.2 Geographic Atrophy Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Geographic Atrophy Market: Disease Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Therapy Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Therapy Success Rate
7 Geographic Atrophy Market Epidemiology Scenario and Forecast – 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2017-2032)
7.1.1 Prevalence, by Country
7.1.1.1 U.S.
7.1.1.2 U.K.
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Mortality by Country
7.1.2.1 U.S.
7.1.2.2 U.K.
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment Seeking Rate by Country
7.1.3.1 U.S.
7.1.3.2 U.K.
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Geographic Atrophy Market Landscape: 8 Major Market*
8.1 Geographic Atrophy Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Geographic Atrophy Market: Product Landscape
8.2.1 Analysis by Treatment
9 Geographic Atrophy Market Challenges and Unmet Needs
9.1 Therapy Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Therapy
11 Geographic Atrophy: Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Geographic Atrophy Market Segmentation: 8 Major Markets
12.1 Geographic Atrophy Market by Age Group
12.1.1 Market Overview
12.1.2 60-75 Years
12.1.3 Above 75 Years
12.2 Geographic Atrophy Market by Treatment
12.2.1 Market Overview
12.2.2 Medications
12.2.3 Supplements
12.2.4 Others
12.3 Geographic Atrophy Market by Distribution Channel
12.3.1 Market Overview
12.3.2 Hospital Pharmacy
12.3.3 Retail Pharmacy
12.3.4 Online Pharmacy
12.4 Geographic Atrophy Market by Region
12.4.1 Market Overview
12.4.2 United States
12.4.3 EU-4 and the United Kingdom
12.4.3.1 Germany
12.4.3.2 France
12.4.3.3 Italy
12.4.3.4 Spain
12.4.3.5 United Kingdom
12.4.4 Japan
12.4.5 India
13 United States Geographic Atrophy Market (2017-2032)
13.1 United States Geographic Atrophy Market Historical Value (2017-2023)
13.2 United States Geographic Atrophy Market Forecast Value (2024-2032)
13.3 United States Geographic Atrophy Market by Age Group
13.3.1 Market Overview
13.3.2 60-75 Years
13.3.3 Above 75 Years
13.4 United States Geographic Atrophy Market by Treatment
13.4.1 Market Overview
13.4.2 Medications
13.4.3 Supplements
13.4.4 Others
13.5 United States Geographic Atrophy Market by Distribution Channel
13.5.1 Market Overview
13.5.2 Hospital Pharmacy
13.5.3 Retail Pharmacy
13.5.4 Online Pharmacy
14 EU-4 and United Kingdom Geographic Atrophy Market (2017-2032)
14.1 EU-4 and United Kingdom Geographic Atrophy Market Historical Value (2017-2023)
14.2 EU-4 and United Kingdom Geographic Atrophy Market Forecast Value (2024-2032)
14.3 EU-4 and United Kingdom Geographic Atrophy Market by Age Group
14.3.1 Market Overview
14.3.2 60-75 Years
14.3.3 Above 75 Years
14.4 EU-4 and United Kingdom Geographic Atrophy Market by Treatment
14.4.1 Market Overview
14.4.2 Medications
14.4.3 Supplements
14.4.4 Others
14.5 EU-4 and United Kingdom Geographic Atrophy Market by Distribution Channel
14.5.1 Market Overview
14.5.2 Hospital Pharmacy
14.5.3 Retail Pharmacy
14.5.4 Online Pharmacy
15 Japan Geographic Atrophy Market
15.1 Japan Geographic Atrophy Market Historical Value (2017-2023)
15.2 Japan Geographic Atrophy Market Forecast Value (2024-2032)
15.3 Japan Geographic Atrophy Market by Age Group
15.3.1 Market Overview
15.3.2 60-75 Years
15.3.3 Above 75 Years
15.4 Japan Geographic Atrophy Market by Treatment
15.4.1 Market Overview
15.4.2 Medications
15.4.3 Supplements
15.4.4 Others
15.5 Japan Geographic Atrophy Market by Distribution Channel
15.5.1 Market Overview
15.5.2 Hospital Pharmacy
15.5.3 Retail Pharmacy
15.5.4 Online Pharmacy
16 India Geographic Atrophy Market
16.1 India Geographic Atrophy Market (2017-2032) Historical Value (2017-2023)
16.2 India Geographic Atrophy Market (2017-2032) Forecast Value (2024-2032)
16.3 India Geographic Atrophy Market by Age Group
16.3.1 Market Overview
16.3.2 60-75 Years
16.3.3 Above 75 Years
16.4 India Geographic Atrophy Market by Treatment
16.4.1 Market Overview
16.4.2 Medications
16.4.3 Supplements
16.4.4 Others
16.5 India Geographic Atrophy Market by Distribution Channel
16.5.1 Market Overview
16.5.2 Hospital Pharmacy
16.5.3 Retail Pharmacy
16.5.4 Online Pharmacy
17 Regulatory Framework
17.1 Regulatory Overview
17.2 US FDA
17.3 EU EMA
17.4 INDIA CDSCO
17.5 JAPAN PMDA
17.6 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Clinical Trial Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Grant Analysis
20.1 Analysis by Year
20.2 Analysis by Amount Awarded
20.3 Analysis by Issuing Authority
20.4 Analysis by Grant Product
20.5 Analysis by Funding Institute
20.6 Analysis by Departments
20.7 Analysis by Recipient Organization
21 Strategic Initiatives
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Funding and Investment Analysis
22.1 Analysis by Funding Instances
22.2 Analysis by Type of Funding
22.3 Analysis by Funding Amount
22.4 Analysis by Leading Players
22.5 Analysis by Leading Investors
22.6 Analysis by Geography
23 Supplier Landscape
23.1 Market Share by Top 5 Companies
23.2 Apellis Pharmaceuticals, Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Iveric Bio
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Alkeus Pharmaceuticals Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Hemera Biosciences
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Allegro Ophthalmics
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Stealth BioTherapeutics
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Novartis AG
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Regenerative Patch Technologies, LLC
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 F. Hoffmann-La Roche AG
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Gensight Biologics
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 NGM Biopharmaceuticals
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 AstraZeneca PLC
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Lineage Cell Therapeutics
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
24 Geographic Atrophy Market – Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER